Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022398 | 0.91 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL12022535 | 0.91 | — | — | |
| SCHEMBL12022490 | 0.88 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL1119494 | 0.87 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL8077178 | 0.86 | — | — | |
| SCHEMBL13882786 | 0.86 | — | — | |
| SCHEMBL12022533 | 0.86 | — | — | |
| SCHEMBL12022493 | 0.83 | — | — | |
| SCHEMBL12022503 | 0.83 | — | — | |
| SCHEMBL12022512 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-2906579-B1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| EP-2906579-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX Pharmaceuticals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140099283-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | UNIVERSITE DE MONTPELLIER (FR) | 2014-04-10 | — | — | US | disclosed |
| US-20090093425-A1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093425-A1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093425-A1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099283-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CA12 3354/4885CA1 4616/4885CA2 3286/4885 |
| US-20090093425-A1 | TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS BY REVERSIBLE PHOSPHOTRIESTER CHARGE NEUTRALIZATION PROTECTING GROUPS | NSUN3, POLRMT, NSUN2 | CA12 422/4885CA1 836/4885CA2 1611/4885 |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CA12 3354/4885CA1 4616/4885CA2 3286/4885 |
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | PNP, MTAP, TYMP | CA12 2983/4885CA1 3738/4885CA2 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.